Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 May;38(5):911–917. doi: 10.1128/aac.38.5.911

Strategies in prevention of invasive pulmonary aspergillosis in immunosuppressed or neutropenic patients.

J Beyer 1, S Schwartz 1, V Heinemann 1, W Siegert 1
PMCID: PMC188126  PMID: 8067770

Full text

PDF
913

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allo M. D., Miller J., Townsend T., Tan C. Primary cutaneous aspergillosis associated with Hickman intravenous catheters. N Engl J Med. 1987 Oct 29;317(18):1105–1108. doi: 10.1056/NEJM198710293171802. [DOI] [PubMed] [Google Scholar]
  2. Anaissie E. Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clin Infect Dis. 1992 Mar;14 (Suppl 1):S43–S53. doi: 10.1093/clinids/14.supplement_1.s43. [DOI] [PubMed] [Google Scholar]
  3. Andriole V. T., Miniter P., George D., Kordick D., Patterson T. F. Animal models: usefulness for studies of fungal pathogenesis and drug efficacy in aspergillosis. Clin Infect Dis. 1992 Mar;14 (Suppl 1):S134–S138. doi: 10.1093/clinids/14.supplement_1.s134. [DOI] [PubMed] [Google Scholar]
  4. Armstrong D. Symposium on infectious complications of neoplastic disease (Part II). Protected environments are discomforting and expensive and do not offer meaningful protection. Am J Med. 1984 Apr;76(4):685–689. doi: 10.1016/0002-9343(84)90295-x. [DOI] [PubMed] [Google Scholar]
  5. Benhamou E., Hartmann O., Noguès C., Maraninchi D., Valteau D., Lemerle J. Does ketoconazole prevent fungal infection in children treated with high dose chemotherapy and bone marrow transplantation? Results of a randomized placebo-controlled trial. Bone Marrow Transplant. 1991 Feb;7(2):127–131. [PubMed] [Google Scholar]
  6. Beyer J., Barzen G., Risse G., Weyer C., Miksits K., Dullenkopf K., Huhn D., Siegert W. Aerosol amphotericin B for prevention of invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 1993 Jun;37(6):1367–1369. doi: 10.1128/aac.37.6.1367. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Bodey G. P. Azole antifungal agents. Clin Infect Dis. 1992 Mar;14 (Suppl 1):S161–S169. doi: 10.1093/clinids/14.supplement_1.s161. [DOI] [PubMed] [Google Scholar]
  8. Bodey G. P., Vartivarian S. Aspergillosis. Eur J Clin Microbiol Infect Dis. 1989 May;8(5):413–437. doi: 10.1007/BF01964057. [DOI] [PubMed] [Google Scholar]
  9. Bodey G., Bueltmann B., Duguid W., Gibbs D., Hanak H., Hotchi M., Mall G., Martino P., Meunier F., Milliken S. Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infect Dis. 1992 Feb;11(2):99–109. doi: 10.1007/BF01967060. [DOI] [PubMed] [Google Scholar]
  10. Boogaerts M. A., Verhoef G. E., Zachee P., Demuynck H., Verbist L., De Beule K. Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses. 1989;32 (Suppl 1):103–108. doi: 10.1111/j.1439-0507.1989.tb02299.x. [DOI] [PubMed] [Google Scholar]
  11. Brajtburg J., Powderly W. G., Kobayashi G. S., Medoff G. Amphotericin B: delivery systems. Antimicrob Agents Chemother. 1990 Mar;34(3):381–384. doi: 10.1128/aac.34.3.381. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Burch P. A., Karp J. E., Merz W. G., Kuhlman J. E., Fishman E. K. Favorable outcome of invasive aspergillosis in patients with acute leukemia. J Clin Oncol. 1987 Dec;5(12):1985–1993. doi: 10.1200/JCO.1987.5.12.1985. [DOI] [PubMed] [Google Scholar]
  13. Caillot D., Chavanet P., Casasnovas O., Solary E., Zanetta G., Buisson M., Wagner O., Cuisenier B., Bonnin A., Camerlynck P. Clinical evaluation of a new lipid-based delivery system for intravenous administration of amphotericin B. Eur J Clin Microbiol Infect Dis. 1992 Aug;11(8):722–725. doi: 10.1007/BF01989977. [DOI] [PubMed] [Google Scholar]
  14. Cauwenbergh G., De Doncker P., Stoops K., De Dier A. M., Goyvaerts H., Schuermans V. Itraconazole in the treatment of human mycoses: review of three years of clinical experience. Rev Infect Dis. 1987 Jan-Feb;9 (Suppl 1):S146–S152. doi: 10.1093/clinids/9.supplement_1.s146. [DOI] [PubMed] [Google Scholar]
  15. Christiansen K. J., Bernard E. M., Gold J. W., Armstrong D. Distribution and activity of amphotericin B in humans. J Infect Dis. 1985 Nov;152(5):1037–1043. doi: 10.1093/infdis/152.5.1037. [DOI] [PubMed] [Google Scholar]
  16. Cohen M. S., Isturiz R. E., Malech H. L., Root R. K., Wilfert C. M., Gutman L., Buckley R. H. Fungal infection in chronic granulomatous disease. The importance of the phagocyte in defense against fungi. Am J Med. 1981 Jul;71(1):59–66. doi: 10.1016/0002-9343(81)90259-x. [DOI] [PubMed] [Google Scholar]
  17. Collette N., van der Auwera P., Lopez A. P., Heymans C., Meunier F. Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B-deoxycholate. Antimicrob Agents Chemother. 1989 Mar;33(3):362–368. doi: 10.1128/aac.33.3.362. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Conneally E., Cafferkey M. T., Daly P. A., Keane C. T., McCann S. R. Nebulized amphotericin B as prophylaxis against invasive aspergillosis in granulocytopenic patients. Bone Marrow Transplant. 1990 Jun;5(6):403–406. [PubMed] [Google Scholar]
  19. Davis I., Morstyn G. Clinical uses of growth factors. Baillieres Clin Haematol. 1992 Jul;5(3):753–786. doi: 10.1016/s0950-3536(11)80016-8. [DOI] [PubMed] [Google Scholar]
  20. DeGregorio M. W., Lee W. M., Linker C. A., Jacobs R. A., Ries C. A. Fungal infections in patients with acute leukemia. Am J Med. 1982 Oct;73(4):543–548. doi: 10.1016/0002-9343(82)90334-5. [DOI] [PubMed] [Google Scholar]
  21. Denning D. W., Follansbee S. E., Scolaro M., Norris S., Edelstein H., Stevens D. A. Pulmonary aspergillosis in the acquired immunodeficiency syndrome. N Engl J Med. 1991 Mar 7;324(10):654–662. doi: 10.1056/NEJM199103073241003. [DOI] [PubMed] [Google Scholar]
  22. Denning D. W., Stevens D. A. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis. 1990 Nov-Dec;12(6):1147–1201. doi: 10.1093/clinids/12.6.1147. [DOI] [PubMed] [Google Scholar]
  23. Denning D. W., Tucker R. M., Hanson L. H., Stevens D. A. Treatment of invasive aspergillosis with itraconazole. Am J Med. 1989 Jun;86(6 Pt 2):791–800. doi: 10.1016/0002-9343(89)90475-0. [DOI] [PubMed] [Google Scholar]
  24. Fainstein V., Bodey G. P., Elting L., Maksymiuk A., Keating M., McCredie K. B. Amphotericin B or ketoconazole therapy of fungal infections in neutropenic cancer patients. Antimicrob Agents Chemother. 1987 Jan;31(1):11–15. doi: 10.1128/aac.31.1.11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Gallis H. A., Drew R. H., Pickard W. W. Amphotericin B: 30 years of clinical experience. Rev Infect Dis. 1990 Mar-Apr;12(2):308–329. doi: 10.1093/clinids/12.2.308. [DOI] [PubMed] [Google Scholar]
  26. Gerson S. L., Talbot G. H., Hurwitz S., Strom B. L., Lusk E. J., Cassileth P. A. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med. 1984 Mar;100(3):345–351. doi: 10.7326/0003-4819-100-3-345. [DOI] [PubMed] [Google Scholar]
  27. Gerson S. L., Talbot G. H., Lusk E., Hurwitz S., Strom B. L., Cassileth P. A. Invasive pulmonary aspergillosis in adult acute leukemia: clinical clues to its diagnosis. J Clin Oncol. 1985 Aug;3(8):1109–1116. doi: 10.1200/JCO.1985.3.8.1109. [DOI] [PubMed] [Google Scholar]
  28. Gilbert B. E., Wyde P. R., Wilson S. Z. Aerosolized liposomal amphotericin B for treatment of pulmonary and systemic Cryptococcus neoformans infections in mice. Antimicrob Agents Chemother. 1992 Jul;36(7):1466–1471. doi: 10.1128/aac.36.7.1466. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Goodman J. L., Winston D. J., Greenfield R. A., Chandrasekar P. H., Fox B., Kaizer H., Shadduck R. K., Shea T. C., Stiff P., Friedman D. J. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992 Mar 26;326(13):845–851. doi: 10.1056/NEJM199203263261301. [DOI] [PubMed] [Google Scholar]
  30. Grant S. M., Clissold S. P. Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs. 1989 Mar;37(3):310–344. doi: 10.2165/00003495-198937030-00003. [DOI] [PubMed] [Google Scholar]
  31. Gryn J., Goldberg J., Johnson E., Siegel J., Inzerillo J. The toxicity of daily inhaled amphotericin B. Am J Clin Oncol. 1993 Feb;16(1):43–46. doi: 10.1097/00000421-199302000-00011. [DOI] [PubMed] [Google Scholar]
  32. Gustafson T. L., Schaffner W., Lavely G. B., Stratton C. W., Johnson H. K., Hutcheson R. H., Jr Invasive aspergillosis in renal transplant recipients: correlation with corticosteroid therapy. J Infect Dis. 1983 Aug;148(2):230–238. doi: 10.1093/infdis/148.2.230. [DOI] [PubMed] [Google Scholar]
  33. Hector R. F., Yee E. Evaluation of Bay R 3783 in rodent models of superficial and systemic candidiasis, meningeal cryptococcosis, and pulmonary aspergillosis. Antimicrob Agents Chemother. 1990 Mar;34(3):448–454. doi: 10.1128/aac.34.3.448. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Heel R. C., Brogden R. N., Pakes G. E., Speight T. M., Avery G. S. Miconazole: a preliminary review of its therapeutic efficacy in systemic fungal infections. Drugs. 1980 Jan;19(1):7–30. doi: 10.2165/00003495-198019010-00002. [DOI] [PubMed] [Google Scholar]
  35. Ikemoto H. A clinical study of fluconazole for the treatment of deep mycoses. Diagn Microbiol Infect Dis. 1989 Jul-Aug;12(4 Suppl):239S–247S. doi: 10.1016/0732-8893(89)90143-0. [DOI] [PubMed] [Google Scholar]
  36. Jeffery G. M., Beard M. E., Ikram R. B., Chua J., Allen J. R., Heaton D. C., Hart D. N., Schousboe M. I. Intranasal amphotericin B reduces the frequency of invasive aspergillosis in neutropenic patients. Am J Med. 1991 Jun;90(6):685–692. [PubMed] [Google Scholar]
  37. Jorgensen C. J., Dreyfus F., Vaixeler J., Guyomard S., Massiot C., Belanger C., Brunet F., Giraud T., Dupuis-Camay P. Failure of amphotericin B spray to prevent aspergillosis in granulocytopenic patients. Nouv Rev Fr Hematol. 1989;31(5):327–328. [PubMed] [Google Scholar]
  38. KILBURN K. H. The innocuousness and possible therapeutic use of aerosol amphotericin-B. Am Rev Respir Dis. 1959 Sep;80:441–442. doi: 10.1164/arrd.1959.80.3.441. [DOI] [PubMed] [Google Scholar]
  39. Karp J. E., Burch P. A., Merz W. G. An approach to intensive antileukemia therapy in patients with previous invasive aspergillosis. Am J Med. 1988 Aug;85(2):203–206. doi: 10.1016/s0002-9343(88)80343-7. [DOI] [PubMed] [Google Scholar]
  40. Karp J. E., Merz W. G., Charache P. Response to empiric amphotericin B during antileukemic therapy-induced granulocytopenia. Rev Infect Dis. 1991 Jul-Aug;13(4):592–599. doi: 10.1093/clinids/13.4.592. [DOI] [PubMed] [Google Scholar]
  41. Levitz S. M. Overview of host defenses in fungal infections. Clin Infect Dis. 1992 Mar;14 (Suppl 1):S37–S42. doi: 10.1093/clinids/14.supplement_1.s37. [DOI] [PubMed] [Google Scholar]
  42. Löwenberg B., Touw I. P. Hematopoietic growth factors and their receptors in acute leukemia. Blood. 1993 Jan 15;81(2):281–292. [PubMed] [Google Scholar]
  43. Metcalf D. Control of granulocytes and macrophages: molecular, cellular, and clinical aspects. Science. 1991 Oct 25;254(5031):529–533. doi: 10.1126/science.1948028. [DOI] [PubMed] [Google Scholar]
  44. Meunier F. New methods for delivery of antifungal agents. Rev Infect Dis. 1989 Nov-Dec;11 (Suppl 7):S1605–S1612. doi: 10.1093/clinids/11.supplement_7.s1605. [DOI] [PubMed] [Google Scholar]
  45. Meunier F., Prentice H. G., Ringdén O. Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J Antimicrob Chemother. 1991 Oct;28 (Suppl B):83–91. doi: 10.1093/jac/28.suppl_b.83. [DOI] [PubMed] [Google Scholar]
  46. Meunier F. Prevention and mycoses in immunocompromised patients. Rev Infect Dis. 1987 Mar-Apr;9(2):408–416. doi: 10.1093/clinids/9.2.408. [DOI] [PubMed] [Google Scholar]
  47. Meyers J. D. Fungal infections in bone marrow transplant patients. Semin Oncol. 1990 Jun;17(3 Suppl 6):10–13. [PubMed] [Google Scholar]
  48. Milliken S. T., Powles R. L. Antifungal prophylaxis in bone marrow transplantation. Rev Infect Dis. 1990 Mar-Apr;12 (Suppl 3):S374–S379. doi: 10.1093/clinids/12.supplement_3.s374. [DOI] [PubMed] [Google Scholar]
  49. Moreau P., Milpied N., Fayette N., Ramée J. F., Harousseau J. L. Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients. J Antimicrob Chemother. 1992 Oct;30(4):535–541. doi: 10.1093/jac/30.4.535. [DOI] [PubMed] [Google Scholar]
  50. Myers S. E., Devine S. M., Topper R. L., Ondrey M., Chandler C., O'Toole K., Williams S. F., Larson R. A., Geller R. B. A pilot study of prophylactic aerosolized amphotericin B in patients at risk for prolonged neutropenia. Leuk Lymphoma. 1992 Oct;8(3):229–233. doi: 10.3109/10428199209054909. [DOI] [PubMed] [Google Scholar]
  51. Nemunaitis J., Meyers J. D., Buckner C. D., Shannon-Dorcy K., Mori M., Shulman H., Bianco J. A., Higano C. S., Groves E., Storb R. Phase I trial of recombinant human macrophage colony-stimulating factor in patients with invasive fungal infections. Blood. 1991 Aug 15;78(4):907–913. [PubMed] [Google Scholar]
  52. Nemunaitis J., Shannon-Dorcy K., Appelbaum F. R., Meyers J., Owens A., Day R., Ando D., O'Neill C., Buckner D., Singer J. Long-term follow-up of patients with invasive fungal disease who received adjunctive therapy with recombinant human macrophage colony-stimulating factor. Blood. 1993 Sep 1;82(5):1422–1427. [PubMed] [Google Scholar]
  53. Niki Y., Bernard E. M., Edwards F. F., Schmitt H. J., Yu B., Armstrong D. Model of recurrent pulmonary aspergillosis in rats. J Clin Microbiol. 1991 Jul;29(7):1317–1322. doi: 10.1128/jcm.29.7.1317-1322.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Niki Y., Bernard E. M., Schmitt H. J., Tong W. P., Edwards F. F., Armstrong D. Pharmacokinetics of aerosol amphotericin B in rats. Antimicrob Agents Chemother. 1990 Jan;34(1):29–32. doi: 10.1128/aac.34.1.29. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Opal S. M., Asp A. A., Cannady P. B., Jr, Morse P. L., Burton L. J., Hammer P. G., 2nd Efficacy of infection control measures during a nosocomial outbreak of disseminated aspergillosis associated with hospital construction. J Infect Dis. 1986 Mar;153(3):634–637. doi: 10.1093/infdis/153.3.634. [DOI] [PubMed] [Google Scholar]
  56. Palmer L. B., Greenberg H. E., Schiff M. J. Corticosteroid treatment as a risk factor for invasive aspergillosis in patients with lung disease. Thorax. 1991 Jan;46(1):15–20. doi: 10.1136/thx.46.1.15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Pannuti C. S., Gingrich R. D., Pfaller M. A., Wenzel R. P. Nosocomial pneumonia in adult patients undergoing bone marrow transplantation: a 9-year study. J Clin Oncol. 1991 Jan;9(1):77–84. doi: 10.1200/JCO.1991.9.1.77. [DOI] [PubMed] [Google Scholar]
  58. Patterson T. F., George D., Miniter P., Andriole V. T. The role of fluconazole in the early treatment and prophylaxis of experimental invasive aspergillosis. J Infect Dis. 1991 Sep;164(3):575–580. doi: 10.1093/infdis/164.3.575. [DOI] [PubMed] [Google Scholar]
  59. Patterson T. F., Miniter P., Andriole V. T. Efficacy of fluconazole in experimental invasive aspergillosis. Rev Infect Dis. 1990 Mar-Apr;12 (Suppl 3):S281–S285. doi: 10.1093/clinids/12.supplement_3.s281. [DOI] [PubMed] [Google Scholar]
  60. Perfect J. R., Klotman M. E., Gilbert C. C., Crawford D. D., Rosner G. L., Wright K. A., Peters W. P. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis. 1992 May;165(5):891–897. doi: 10.1093/infdis/165.5.891. [DOI] [PubMed] [Google Scholar]
  61. Perfect J. R., Pickard W. W., Hunt D. L., Palmer B., Schell W. A. The use of amphotericin B in nosocomial fungal infection. Rev Infect Dis. 1991 May-Jun;13(3):474–479. doi: 10.1093/clinids/13.3.474. [DOI] [PubMed] [Google Scholar]
  62. Persat F., Marzullo C., Guyotat D., Rochet M. J., Piens M. A. Plasma itraconazole concentrations in neutropenic patients after repeated high-dose treatment. Eur J Cancer. 1992;28A(4-5):838–841. doi: 10.1016/0959-8049(92)90127-n. [DOI] [PubMed] [Google Scholar]
  63. Pizzo P. A., Robichaud K. J., Gill F. A., Witebsky F. G. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med. 1982 Jan;72(1):101–111. doi: 10.1016/0002-9343(82)90594-0. [DOI] [PubMed] [Google Scholar]
  64. Polak-Wyss A. Protective effect of human granulocyte colony-stimulating factor (hG-CSF) on Cryptococcus and Aspergillus infections in normal and immunosuppressed mice. Mycoses. 1991 May-Jun;34(5-6):205–215. doi: 10.1111/j.1439-0507.1991.tb00645.x. [DOI] [PubMed] [Google Scholar]
  65. Quist P., Tauris P. Short-term curative treatment of Aspergillus fumigatus pneumonia with fluconazole. Scand J Infect Dis. 1990;22(6):749–750. doi: 10.3109/00365549009027132. [DOI] [PubMed] [Google Scholar]
  66. Reents S., Goodwin S. D., Singh V. Antifungal prophylaxis in immunocompromised hosts. Ann Pharmacother. 1993 Jan;27(1):53–60. doi: 10.1177/106002809302700114. [DOI] [PubMed] [Google Scholar]
  67. Rhame F. S. Prevention of nosocomial aspergillosis. J Hosp Infect. 1991 Jun;18 (Suppl A):466–472. doi: 10.1016/0195-6701(91)90058-g. [DOI] [PubMed] [Google Scholar]
  68. Rhame F. S., Streifel A. J., Kersey J. H., Jr, McGlave P. B. Extrinsic risk factors for pneumonia in the patient at high risk of infection. Am J Med. 1984 May 15;76(5A):42–52. doi: 10.1016/0002-9343(84)90243-2. [DOI] [PubMed] [Google Scholar]
  69. Richard C., Romón I., Baro J., Insunza A., Loyola I., Zurbano F., Tapia M., Iriondo A., Conde E., Zubizarreta A. Invasive pulmonary aspergillosis prior to BMT in acute leukemia patients does not predict a poor outcome. Bone Marrow Transplant. 1993 Sep;12(3):237–241. [PubMed] [Google Scholar]
  70. Robertson M. J., Larson R. A. Recurrent fungal pneumonias in patients with acute nonlymphocytic leukemia undergoing multiple courses of intensive chemotherapy. Am J Med. 1988 Feb;84(2):233–239. doi: 10.1016/0002-9343(88)90419-6. [DOI] [PubMed] [Google Scholar]
  71. Roilides E., Uhlig K., Venzon D., Pizzo P. A., Walsh T. J. Enhancement of oxidative response and damage caused by human neutrophils to Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immun. 1993 Apr;61(4):1185–1193. doi: 10.1128/iai.61.4.1185-1193.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Rousey S. R., Russler S., Gottlieb M., Ash R. C. Low-dose amphotericin B prophylaxis against invasive Aspergillus infections in allogeneic marrow transplantation. Am J Med. 1991 Nov;91(5):484–492. doi: 10.1016/0002-9343(91)90184-y. [DOI] [PubMed] [Google Scholar]
  73. Rozenberg-Arska M., Dekker A. W., Branger J., Verhoef J. A randomized study to compare oral fluconazole to amphotericin B in the prevention of fungal infections in patients with acute leukaemia. J Antimicrob Chemother. 1991 Mar;27(3):369–376. doi: 10.1093/jac/27.3.369. [DOI] [PubMed] [Google Scholar]
  74. Rubin R. H. The compromised host as sentinel chicken. N Engl J Med. 1987 Oct 29;317(18):1151–1153. doi: 10.1056/NEJM198710293171809. [DOI] [PubMed] [Google Scholar]
  75. Saral R. Candida and Aspergillus infections in immunocompromised patients: an overview. Rev Infect Dis. 1991 May-Jun;13(3):487–492. doi: 10.1093/clinids/13.3.487. [DOI] [PubMed] [Google Scholar]
  76. Saugier-Veber P., Devergie A., Sulahian A., Ribaud P., Traore F., Bourdeau-Esperou H., Gluckman E., Derouin F. Epidemiology and diagnosis of invasive pulmonary aspergillosis in bone marrow transplant patients: results of a 5 year retrospective study. Bone Marrow Transplant. 1993 Aug;12(2):121–124. [PubMed] [Google Scholar]
  77. Schaffner A., Douglas H., Braude A. Selective protection against conidia by mononuclear and against mycelia by polymorphonuclear phagocytes in resistance to Aspergillus. Observations on these two lines of defense in vivo and in vitro with human and mouse phagocytes. J Clin Invest. 1982 Mar;69(3):617–631. doi: 10.1172/JCI110489. [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Schmitt H. J., Bernard E. M., Edwards F. F., Armstrong D. Combination therapy in a model of pulmonary aspergillosis. Mycoses. 1991 Jul-Aug;34(7-8):281–285. doi: 10.1111/j.1439-0507.1991.tb00660.x. [DOI] [PubMed] [Google Scholar]
  79. Schmitt H. J., Bernard E. M., Häuser M., Armstrong D. Aerosol amphotericin B is effective for prophylaxis and therapy in a rat model of pulmonary aspergillosis. Antimicrob Agents Chemother. 1988 Nov;32(11):1676–1679. doi: 10.1128/aac.32.11.1676. [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Schmitt H. J., Edwards F., Andrade J., Niki Y., Armstrong D. Comparison of azoles against aspergilli in vitro and in an experimental model of pulmonary aspergillosis. Chemotherapy. 1992;38(2):118–126. doi: 10.1159/000238951. [DOI] [PubMed] [Google Scholar]
  81. Shepp D. H., Klosterman A., Siegel M. S., Meyers J. D. Comparative trial of ketoconazole and nystatin for prevention of fungal infection in neutropenic patients treated in a protective environment. J Infect Dis. 1985 Dec;152(6):1257–1263. doi: 10.1093/infdis/152.6.1257. [DOI] [PubMed] [Google Scholar]
  82. Sherertz R. J., Belani A., Kramer B. S., Elfenbein G. J., Weiner R. S., Sullivan M. L., Thomas R. G., Samsa G. P. Impact of air filtration on nosocomial Aspergillus infections. Unique risk of bone marrow transplant recipients. Am J Med. 1987 Oct;83(4):709–718. doi: 10.1016/0002-9343(87)90902-8. [DOI] [PubMed] [Google Scholar]
  83. Talbot G. H., Huang A., Provencher M. Invasive aspergillus rhinosinusitis in patients with acute leukemia. Rev Infect Dis. 1991 Mar-Apr;13(2):219–232. doi: 10.1093/clinids/13.2.219. [DOI] [PubMed] [Google Scholar]
  84. Thunnissen P. L., Sizoo W., Hendriks W. D. Safety and efficacy of itraconazole in prevention of fungal infections in neutropenic patients. Neth J Med. 1991 Aug;39(1-2):84–91. [PubMed] [Google Scholar]
  85. Tricot G., Joosten E., Boogaerts M. A., Vande Pitte J., Cauwenbergh G. Ketoconazole vs. itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two nonrandomized studies. Rev Infect Dis. 1987 Jan-Feb;9 (Suppl 1):S94–S99. doi: 10.1093/clinids/9.supplement_1.s94. [DOI] [PubMed] [Google Scholar]
  86. Troke P. F., Andrews R. J., Marriott M. S., Richardson K. Efficacy of fluconazole (UK-49,858) against experimental aspergillosis and cryptococcosis in mice. J Antimicrob Chemother. 1987 May;19(5):663–670. doi: 10.1093/jac/19.5.663. [DOI] [PubMed] [Google Scholar]
  87. Tucker R. M., Haq Y., Denning D. W., Stevens D. A. Adverse events associated with itraconazole in 189 patients on chronic therapy. J Antimicrob Chemother. 1990 Oct;26(4):561–566. doi: 10.1093/jac/26.4.561. [DOI] [PubMed] [Google Scholar]
  88. Van Cutsem J. In vitro antifungal spectrum of itraconazole and treatment of systemic mycoses with old and new antimycotic agents. Chemotherapy. 1992;38 (Suppl 1):3–11. doi: 10.1159/000239046. [DOI] [PubMed] [Google Scholar]
  89. Van Cutsem J., Van Gerven F., Janssen P. A. Activity of orally, topically, and parenterally administered itraconazole in the treatment of superficial and deep mycoses: animal models. Rev Infect Dis. 1987 Jan-Feb;9 (Suppl 1):S15–S32. doi: 10.1093/clinids/9.supplement_1.s15. [DOI] [PubMed] [Google Scholar]
  90. Van Cutsem J., Van Gerven F., Janssen P. A. Oral and parenteral therapy with saperconazole (R 66905) of invasive aspergillosis in normal and immunocompromised animals. Antimicrob Agents Chemother. 1989 Dec;33(12):2063–2068. doi: 10.1128/aac.33.12.2063. [DOI] [PMC free article] [PubMed] [Google Scholar]
  91. Van Cutsem J., Van Gerven F., Van de Ven M. A., Borgers M., Janssen P. A. Itraconazole, a new triazole that is orally active in aspergillosis. Antimicrob Agents Chemother. 1984 Oct;26(4):527–534. doi: 10.1128/aac.26.4.527. [DOI] [PMC free article] [PubMed] [Google Scholar]
  92. Viollier A. F., Peterson D. E., De Jongh C. A., Newman K. A., Gray W. C., Sutherland J. C., Moody M. A., Schimpff S. C. Aspergillus sinusitis in cancer patients. Cancer. 1986 Jul 15;58(2):366–371. doi: 10.1002/1097-0142(19860715)58:2<366::aid-cncr2820580228>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  93. Viviani M. A., Tortorano A. M., Langer M., Almaviva M., Negri C., Cristina S., Scoccia S., De Maria R., Fiocchi R., Ferrazzi P. Experience with itraconazole in cryptococcosis and aspergillosis. J Infect. 1989 Mar;18(2):151–165. doi: 10.1016/s0163-4453(89)91178-x. [DOI] [PubMed] [Google Scholar]
  94. Vreugdenhil G., Van Dijke B. J., Donnelly J. P., Novakova I. R., Raemaekers J. M., Hoogkamp-Korstanje M. A., Koster M., de Pauw B. E. Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematologic malignancies and intensive chemotherapy. A double blind, placebo controlled study. Leuk Lymphoma. 1993 Nov;11(5-6):353–358. doi: 10.3109/10428199309067926. [DOI] [PubMed] [Google Scholar]
  95. Walsh T. J., Dixon D. M. Nosocomial aspergillosis: environmental microbiology, hospital epidemiology, diagnosis and treatment. Eur J Epidemiol. 1989 Jun;5(2):131–142. doi: 10.1007/BF00156818. [DOI] [PubMed] [Google Scholar]
  96. Walsh T. J., Lee J., Lecciones J., Rubin M., Butler K., Francis P., Weinberger M., Roilides E., Marshall D., Gress J. Empiric therapy with amphotericin B in febrile granulocytopenic patients. Rev Infect Dis. 1991 May-Jun;13(3):496–503. doi: 10.1093/clinids/13.3.496. [DOI] [PubMed] [Google Scholar]
  97. Walsh T. J., Pizzo P. A. Nosocomial fungal infections: a classification for hospital-acquired fungal infections and mycoses arising from endogenous flora or reactivation. Annu Rev Microbiol. 1988;42:517–545. doi: 10.1146/annurev.mi.42.100188.002505. [DOI] [PubMed] [Google Scholar]
  98. Walsh T. J., Rubin M., Hathorn J., Gress J., Thaler M., Skelton J., McKnight J., Browne M., Marshall D., Cotton D. Amphotericin B vs high-dose ketoconazole for empirical antifungal therapy among febrile, granulocytopenic cancer patients. A prospective, randomized study. Arch Intern Med. 1991 Apr;151(4):765–770. [PubMed] [Google Scholar]
  99. Weinberger M., Elattar I., Marshall D., Steinberg S. M., Redner R. L., Young N. S., Pizzo P. A. Patterns of infection in patients with aplastic anemia and the emergence of Aspergillus as a major cause of death. Medicine (Baltimore) 1992 Jan;71(1):24–43. doi: 10.1097/00005792-199201000-00003. [DOI] [PubMed] [Google Scholar]
  100. Wiley J. M., Smith N., Leventhal B. G., Graham M. L., Strauss L. C., Hurwitz C. A., Modlin J., Mellits D., Baumgardner R., Corden B. J. Invasive fungal disease in pediatric acute leukemia patients with fever and neutropenia during induction chemotherapy: a multivariate analysis of risk factors. J Clin Oncol. 1990 Feb;8(2):280–286. doi: 10.1200/JCO.1990.8.2.280. [DOI] [PubMed] [Google Scholar]
  101. Wimperis J. Z., Baglin T. P., Marcus R. E., Warren R. E. An assessment of the efficacy of antimicrobial prophylaxis in bone marrow autografts. Bone Marrow Transplant. 1991 Nov;8(5):363–367. [PubMed] [Google Scholar]
  102. Wingard J. R., Vaughan W. P., Braine H. G., Merz W. G., Saral R. Prevention of fungal sepsis in patients with prolonged neutropenia: a randomized, double-blind, placebo-controlled trial of intravenous miconazole. Am J Med. 1987 Dec;83(6):1103–1110. doi: 10.1016/0002-9343(87)90949-1. [DOI] [PubMed] [Google Scholar]
  103. Winston D. J., Chandrasekar P. H., Lazarus H. M., Goodman J. L., Silber J. L., Horowitz H., Shadduck R. K., Rosenfeld C. S., Ho W. G., Islam M. Z. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med. 1993 Apr 1;118(7):495–503. doi: 10.7326/0003-4819-118-7-199304010-00003. [DOI] [PubMed] [Google Scholar]
  104. van't Wout J. W., Novakova I., Verhagen C. A., Fibbe W. E., de Pauw B. E., van der Meer J. W. The efficacy of itraconazole against systemic fungal infections in neutropenic patients: a randomised comparative study with amphotericin B. J Infect. 1991 Jan;22(1):45–52. doi: 10.1016/0163-4453(91)90954-q. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES